$BEAT

HeartBeam, Inc. (BEAT): Submission of Matters to a Vote of Security Holders

HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On July 31, 2026, HeartBeam, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”) virtually, via live webcast. As of the close of business on June 5, 2026, the record date for the Annual M

Original reporting
Published Aug 3, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BEAT
Neutral
medium confidence
Mentioned
$BEAT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BEATNeutralLow
01

Why it matters

Director nominees were elected and the independent auditor ratification passed, while the proposal to amend the 2022 Equity Incentive Plan to add 3,000,000 authorized shares was not approved.

02

Market read

Traders may monitor whether the failed equity plan amendment leads to a resubmission or alternative compensation approach, but the filing itself is not a fundamental catalyst.

03

What to watch

The filing does not state whether the company will resubmit the proposal, adjust the plan, or pursue alternative equity compensation structures, so the practical impact may be smaller than the vote result suggests.

Relevance 6/10Novelty 2/10Timing: after-hours filing of July 31 annual meeting vote results (filed Aug 3, 2026)

Background

This is an SEC Form 8-K under Item 5.07 summarizing matters voted on at HeartBeam’s annual meeting held virtually on July 31, 2026.

Company-level read

Ticker impact

$BEATNeutralMedium confidence
Context

HeartBeam filed an 8-K reporting the results of its July 31, 2026 annual meeting, including director elections and a failed equity plan amendment.

Expected impact

Likely limited near-term impact; any reaction would be second-order and depends on how investors view the failed plan amendment.

Evidence & confidence

8-K Item 5.07 discloses vote tallies. It does not include new financial guidance, transactions, or regulatory outcomes. The failed proposal could affect future compensation flexibility, but the article provides no follow-on actions or timeline.

Market effects

Minimal. Governance vote outcomes are not typically sector-moving without accompanying financing, restructuring, or regulatory developments.

Minimal.

Minimal.

Counterpoint

The failed equity plan amendment could signal shareholder resistance to dilution, which may constrain future hiring/retention plans and indirectly pressure sentiment if compensation needs are urgent.

Key entities

  • HeartBeam, Inc.

    NASDAQ-listed company whose annual meeting vote results are reported in the 8-K.

  • CBIZ CPAs P.C.

    Independent registered public accounting firm whose appointment was ratified for fiscal year ending Dec. 31, 2026.

Related articles

$BEATMedAI 8/10

Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news

H.C. Wainwright maintained a Neutral rating on Heartbeam Inc. (BEAT) after its HeartBeam System received FDA Breakthrough Device designation. The stock rose 78% to $0.65, with a market cap of $36.86M. The designation, based on ALIGN-ACS study data, expedites Medicare coverage. BEAT reported a Q2 EPS of -$1.10, missing estimates by $1.01, and plans a $25M equity offering.

$BEATHighAI 8/10

Why is Heartbeam stock surging today?

HeartBeam's stock rose 56.6% after the FDA granted Breakthrough Device Designation for its HeartBeam System, a tool for evaluating potential heart attacks. The designation was granted in 30 days, ahead of the standard 60-day review period. HeartBeam estimates the heart attack assessment market at $15 billion, with a broader cardiac platform opportunity exceeding $40 billion. The NASDAQ and S&P 500 also saw modest gains.

$BEATHighAI 9/10

HeartBeam stock soars on FDA breakthrough designation

HeartBeam Inc (BEAT) shares rose 90% after the FDA granted Breakthrough Device Designation for its at-home heart attack assessment tool. The designation accelerates FDA review and opens expedited Medicare coverage pathways. HeartBeam estimates the heart attack market opportunity at $15 billion. The company plans to seek FDA alignment on a pivotal study design and begin patient enrollment soon.

$BEATMed

Why is Heartbeam stock sliding today?

Heartbeam Inc shares fell 1.7% after hours to $0.58 after the company reported Q2 2026 results. Net loss was $0.10 per share versus a $0.09 estimate, with operating expenses of $5.1M. Heartbeam lowered full-year 2026 cash outflow guidance and said ALIGN-ACS pilot enrollment was completed early.

$PCVXHighAI 9/10

Vaxcyte prices US$1B stock, warrants and notes

Vaxcyte, Inc. (NASDAQ: PCVX) raised about US$1B through concurrent stock, warrant, and convertible-note offerings. The company plans to use proceeds for clinical trials, manufacturing, and potential U.S. launch of its pneumococcal vaccine VAX-31. Vaxcyte's shares were trading at US$56.48 on Oct. 2, before the offering.